Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February:
Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY.
Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fireside chat on Thursday, February 26, 2026 at 10:40 a.m. ET (virtual).
The events will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcasts will be available on the Lexeo website following the presentations.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy, LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
